Pelthos Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Pelthos Therapeutics Inc 's ROA in the second quarter of 2026?
Pelthos Therapeutics Inc recorded a cumulative net loss of $-86 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -64.75%.

However, within the Healthcare sector 637 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4089, from total ROA ranking in the first quarter of 2026 at 4763.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	16652.39 %	15509.67 %	5786.75 %	5808.39 %	-68.4 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-86	-66	-43	-24	-9
Return On Assets (TTM)	-64.75 %	-66.99 %	-67.87 %	-72.38 %	-599.15 %
PTHS's Total Ranking	# 4089	# 4763	# 4220	# 4841	# 4869
Total Assets (TTM) in million	138	142	127	126	1
Seq. Total Assets Change	-3.08 %	11.86 %	0.56 %	15265.25 %	-9.69 %
Seq. Net Income Change	-	-	-	-	-

PTHS's 5 Years Annual ROA >> Back to PTHS Management Effectiveness >> Compare PTHS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 90
Sector	# 638
Overall	# 4032

Return On Assets Statistics
High	Average	Low
-64.05 %	-241.74 %	-689.52 %
(Jun 30 2026)		(Jun 30 2025)

Financial Statements
Pelthos Therapeutics Inc 's Assets	$ 138 million	PTHS's Balance sheet
Pelthos Therapeutics Inc 's Income	$ -23 million	Quarterly PTHS's Income Statement
PTHS's Income by Division		See PTHS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	9186.32 %	1320.45 %	-	-	-
Total Assets in million	127	1	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-43	-8	-7	0	0
Annual Return On Assets	-34.07 %	-581.03 %	-7657.14 %	-	-

PTHS's 5 Years Annual ROA >> Back to PTHS Management Effectiveness >> Compare PTHS ROA to its Competitors

More Return On Assets Ratios
PTHS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PTHS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PTHS's Competitors
Subscribers only: Roa for Pelthos Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for PTHS's Customers

You may also want to know
PTHS's Roi	PTHS's Inventory Turnover Ratio	PTHS's Growth Rates	PTHS's Dividend Comparisons
	PTHS's Profitability Ratios	PTHS's Asset Turnover Ratio	PTHS's Dividend Growth
PTHS's Roe	PTHS's Valuation Ratios	PTHS's Financial Strength Ratios	PTHS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:42:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.